Glycyx Mor
UEI: C2B7XPCFTHC7
• CAGE: 91G26
Overview
Awardee Type
Parent
Company Description
Glycyx has developed a minimally-toxic cancer therapy that can turn immunologically cold tumors hot. Our lead candidate, axelopran, blocks a fundamental injury response pathway to increase immune infiltration of the tumor microenvironment (TME) and maintain effector phenotype, reducing tumor growth and preventing T-cell exhaustion. Immune potentiation is selectively targeted to the TME, avoiding systemic immune side effects.
Name
Glycyx Mor
Website
Headquarters
San Francisco, CA
United States
United States
Most Recent Award
Sept. 19, 2025
Calculating
Federal grant recipient
GLYCYX MOR, INC.
(UEI C2B7XPCFTHC7, CAGE 91G26)
is headquartered in San Francisco CA.
Its primary registered NAICS is 325412 Pharmaceutical Preparation Manufacturing.
The corporation
was founded in January 2021 and
federally registered in
May 2021.
Federal Award Analysis
Glycyx Mor federal award history
$-
Contracts
$-
Subcontracts
$-
Grants
$-
Subgrants
$-
Total
No Results
Calculating
Calculating
No Results
Calculating
Calculating
No Results
Calculating
Calculating
| Year | Contracts | Subcontracts | Grants | Subgrants |
|---|
No Results
Calculating
Calculating
No Results
Calculating
Calculating
Federal Registration and Certifications
Legal Name
GLYCYX MOR, INC.
Division Number
GLYCYX MOR
UEI
C2B7XPCFTHC7
CAGE Code
91G26
Primary NAICS
SBA Certifications
None
Self Certifications
None
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Contracts and Assistance
Date Founded
Jan. 1, 2021
Initial Registration
May 25, 2021
Last Registration
July 15, 2025
Registration Activation
July 15, 2025
Registration Expiration
July 13, 2026
Fiscal Year End
December 31
Reported Entity Types
For Profit Organization
Manufacturer of Goods
Manufacturer of Goods
State of Incorporation
DE
Country of Incorporation
USA
Employees
<500
Reported NAICS
Accepts Credit Cards
No